PMC:7787218 / 7863-8196 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"108","span":{"begin":9,"end":12},"obj":"Chemical"},{"id":"109","span":{"begin":13,"end":18},"obj":"Chemical"},{"id":"110","span":{"begin":101,"end":112},"obj":"Chemical"}],"attributes":[{"id":"A108","pred":"tao:has_database_id","subj":"108","obj":"MESH:D011092"},{"id":"A109","pred":"tao:has_database_id","subj":"109","obj":"MESH:D008055"},{"id":"A110","pred":"tao:has_database_id","subj":"110","obj":"MESH:D004317"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"d or the PEG-lipid component of the vaccine. By comparison, formulations such as pegylated liposomal doxorubicin are associated with infusion reactions in up to 40% of recipients; the reactions are presumed to be caused by complement activation that occurs on first infusion, without previous exposure to the drug, and they are atten"}